<?xml version='1.0' encoding='utf-8'?>
<document id="22615059"><sentence text="A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer."><entity charOffset="33-42" id="DDI-PubMed.22615059.s1.e0" text="sunitinib" /><entity charOffset="57-66" id="DDI-PubMed.22615059.s1.e1" text="cisplatin" /><entity charOffset="71-85" id="DDI-PubMed.22615059.s1.e2" text="5-fluorouracil" /><pair ddi="false" e1="DDI-PubMed.22615059.s1.e0" e2="DDI-PubMed.22615059.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22615059.s1.e0" e2="DDI-PubMed.22615059.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22615059.s1.e0" e2="DDI-PubMed.22615059.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22615059.s1.e1" e2="DDI-PubMed.22615059.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22615059.s1.e1" e2="DDI-PubMed.22615059.s1.e2" /></sentence><sentence text="Background This phase I, open-label, dose-escalation study examined the safety, maximum tolerated dose (MTD), and pharmacokinetics of sunitinib plus chemotherapy in patients with advanced gastric cancer"><entity charOffset="134-143" id="DDI-PubMed.22615059.s2.e0" text="sunitinib" /></sentence><sentence text=" Patients and methods Sunitinib (25 or 37"><entity charOffset="22-31" id="DDI-PubMed.22615059.s3.e0" text="Sunitinib" /></sentence><sentence text="5 mg/day, Schedule 2/1: 2 weeks on treatment/1 week off) plus chemotherapy (fixed starting doses of cisplatin 80 mg/m(2) and 5-fluorouracil [5-FU] 4,000 mg/m(2)) was administered to patients with advanced gastric cancer who had not received prior therapy for metastatic disease"><entity charOffset="100-109" id="DDI-PubMed.22615059.s4.e0" text="cisplatin" /><entity charOffset="125-139" id="DDI-PubMed.22615059.s4.e1" text="5-fluorouracil" /><pair ddi="false" e1="DDI-PubMed.22615059.s4.e0" e2="DDI-PubMed.22615059.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22615059.s4.e0" e2="DDI-PubMed.22615059.s4.e1" /></sentence><sentence text=" Results Thirty-four patients were enrolled and received sunitinib 25 mg/day (n = 24) or 37"><entity charOffset="57-66" id="DDI-PubMed.22615059.s5.e0" text="sunitinib" /></sentence><sentence text="5 mg/day (n = 10) plus chemotherapy" /><sentence text=" No dose-limiting toxicity (DLT) was reported in the sunitinib 37"><entity charOffset="53-62" id="DDI-PubMed.22615059.s7.e0" text="sunitinib" /></sentence><sentence text="5 mg cohort" /><sentence text=" However, repeated patterns of myelosuppression beyond the first cycle led to investigation of sunitinib 25 mg/day"><entity charOffset="95-104" id="DDI-PubMed.22615059.s9.e0" text="sunitinib" /></sentence><sentence text=" This was the MTD, and one DLT (grade 3 mucosal inflammation) was reported"><entity charOffset="14-17" id="DDI-PubMed.22615059.s10.e0" text="MTD" /><entity charOffset="27-30" id="DDI-PubMed.22615059.s10.e1" text="DLT" /><pair ddi="false" e1="DDI-PubMed.22615059.s10.e0" e2="DDI-PubMed.22615059.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22615059.s10.e0" e2="DDI-PubMed.22615059.s10.e1" /></sentence><sentence text=" The combination had an acceptable adverse event profile; generally of grade 1/2" /><sentence text=" There was no evidence of a pharmacokinetic drug-drug interaction between sunitinib and 5-FU"><entity charOffset="74-83" id="DDI-PubMed.22615059.s12.e0" text="sunitinib" /><entity charOffset="88-92" id="DDI-PubMed.22615059.s12.e1" text="5-FU" /><pair ddi="false" e1="DDI-PubMed.22615059.s12.e0" e2="DDI-PubMed.22615059.s12.e0" /><pair ddi="false" e1="DDI-PubMed.22615059.s12.e0" e2="DDI-PubMed.22615059.s12.e1" /></sentence><sentence text=" Six patients (26 %) receiving the MTD had a partial response and eight patients experienced stable disease ≥3 months"><entity charOffset="35-38" id="DDI-PubMed.22615059.s13.e0" text="MTD" /></sentence><sentence text=" Conclusions Sunitinib plus cisplatin 80 mg/m(2) and 5-FU 4,000 mg/m(2) were combinable and adverse events were manageable"><entity charOffset="13-22" id="DDI-PubMed.22615059.s14.e0" text="Sunitinib" /><entity charOffset="28-37" id="DDI-PubMed.22615059.s14.e1" text="cisplatin" /><entity charOffset="53-57" id="DDI-PubMed.22615059.s14.e2" text="5-FU" /><pair ddi="false" e1="DDI-PubMed.22615059.s14.e0" e2="DDI-PubMed.22615059.s14.e0" /><pair ddi="false" e1="DDI-PubMed.22615059.s14.e0" e2="DDI-PubMed.22615059.s14.e1" /><pair ddi="false" e1="DDI-PubMed.22615059.s14.e0" e2="DDI-PubMed.22615059.s14.e2" /><pair ddi="false" e1="DDI-PubMed.22615059.s14.e1" e2="DDI-PubMed.22615059.s14.e1" /><pair ddi="false" e1="DDI-PubMed.22615059.s14.e1" e2="DDI-PubMed.22615059.s14.e2" /></sentence><sentence text=" The MTD of sunitinib was established as 25 mg/day on Schedule 2/1"><entity charOffset="12-21" id="DDI-PubMed.22615059.s15.e0" text="sunitinib" /><entity charOffset="5-13" id="DDI-PubMed.22615059.s15.e1" text="MTD" /><pair ddi="false" e1="DDI-PubMed.22615059.s15.e1" e2="DDI-PubMed.22615059.s15.e1" /><pair ddi="false" e1="DDI-PubMed.22615059.s15.e1" e2="DDI-PubMed.22615059.s15.e0" /></sentence><sentence text="" /></document>